eFood

<Previous Article In Issue
Next Article In Issue>
Volume 1, Issue 4, August 2020, Pages 298 - 309

Oral Administration of Oyster Peptide Prevents Bone Loss in Ovariectomized Mice

Authors
Hui Chen1, 2, Pujie Shi3, Zhe Xu1, Fengjiao Fan4, *, Zhenyu Wang1, Ming Du1, *
1School of Food Science and Technology, National Engineering Research Center of Seafood, Dalian Polytechnic University, Dalian, Liaoning 116034, China
2College of Food Science and Technology, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, China
3Department of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin, Heilongjiang 150090, China
4College of Food Science and Engineering, Nanjing University of Finance and Economics, Nanjing, Jiangsu 210046, China
*Corresponding authors. Email: fanfjklyx@nufe.edu.cn; duming@dlpu.edu.cn
Corresponding Authors
Fengjiao Fan, Ming Du
Received 15 July 2020, Accepted 11 August 2020, Available Online 24 August 2020.
DOI
10.2991/efood.k.200812.001How to use a DOI?
Keywords
Osteoporosis; oral administration; bone mineral density; MAPK; ERK
Abstract

Osteoporosis is a disordered metabolic disease occurred congenitally or secondary. Although peptide agents have been approved to prevent osteoporosis administrated through subcutaneous injection, rare reports focused on peptide oral administration for preventive purpose. An eight peptide, P-CG-01 (YRGDVVPK) derived from oyster protein hydrolysates in gastrointestinal tract can promote the proliferation of osteoblast in vitro. In this study, ovariectomized mouse model was used to investigate the osteogenesis activity of P-CG-01. Bone mineral density value was recovered to the level of Sham by treatment of peptide [30 mg/kg body weight (BW)] in the ovariectomized mice. Peptide was detected at an average concentration of 803.16 ng/mL in serum from those mice after gavage. The peptide was labelled with fluorescein isothiocyanate and detected in the cytoplasm of osteoblast by confocal microscopes. ERK2 and BMP-2 expression was increased 1.5- and 3.8-fold, respectively, by the treatment of peptide. Our results suggest that P-CG-01 can inhibit the development of osteoporosis in ovariectomized mice.

Graphical Abstract

Copyright
© 2020 International Association of Dietetic Nutrition and Safety. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Next Article In Issue>
Journal
eFood
Volume-Issue
1 - 4
Pages
298 - 309
Publication Date
2020/08/24
ISSN (Online)
2666-3066
DOI
10.2991/efood.k.200812.001How to use a DOI?
Copyright
© 2020 International Association of Dietetic Nutrition and Safety. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Hui Chen
AU  - Pujie Shi
AU  - Zhe Xu
AU  - Fengjiao Fan
AU  - Zhenyu Wang
AU  - Ming Du
PY  - 2020
DA  - 2020/08/24
TI  - Oral Administration of Oyster Peptide Prevents Bone Loss in Ovariectomized Mice
JO  - eFood
SP  - 298
EP  - 309
VL  - 1
IS  - 4
SN  - 2666-3066
UR  - https://doi.org/10.2991/efood.k.200812.001
DO  - 10.2991/efood.k.200812.001
ID  - Chen2020
ER  -